Jayanta Haldar

Jayanta Haldar

Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), India

Title: Strategies to combat bacterial resistance: Towards development of future antibacterial drugs


Jayanta Haldar is an Assistant Professor at New Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bangalore, India since October 2009. His undergraduate training was at the Presidency College, University of Calcutta and he received his Master of Science and PhD from Indian Institute of Science, Bangalore in 2005. He did Postdoctoral Research from Department of Chemistry, Massachusetts Institute of Technology, USA. His research interests are towards the development of molecular strategies for the prevention and treatment of infectious diseases. He has published more than 30 international peer-reviewed papers, many book chapters and review articles. He has filed various national and international patent applications from 10 different inventions on the development of new drugs and new materials to tackle drug resistance and infections. His research work has been featured in Scientific American, Chemical Engineering News, American Chemical Society, BBC News, Times of India, The Hindu, Rajya Sabha TV, DD India TV etc. He has been awarded as a Ramanujan Fellow from the Department of Science and Technology, Government of India, in 2010. He is an Editorial Board Member of the journal “Microbial Pathogenesis” of Elsevier


Multi-drug resistant Gram-positive bacteria like vancomycin resistant Enterococci (VRE) and Staphylococci (VISA and VRSA); as well as pan-drug resistant New Delhi metallo-β-lactamase-1 (NDM-1) producing Gram-negative bacteria have become a threat to the global public health. The perennial persistence of bacterial resistance, calls for urgent need to develop more potent drugs having new mode of action, which would make bacterial resistance difficult to develop. Recently, we have developed novel vancomycin analogues, which could not only overcome, acquired resistance against VRE, VISA and VRSA but also took care of the inherent vancomycin resistance towards Gram-negative bacteria. Unlike vancomycin, these vancomycin analogues showed the ability to stop the development of bacterial resistance due to incorporation of novel membrane disrupting mechanism. I will also present another strategy where the membrane-active molecules were found to re-sensitize the tetracycline antibiotics to colistin-resistant NDM-1 producing Gram-negative clinical isolates. It was observed that the membrane activity of the molecules provided a backdoor entry to the otherwise excluded antibiotics due to efflux pumps

Speaker Presentations

Speaker PDFs